JP2016540977A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540977A5 JP2016540977A5 JP2016532124A JP2016532124A JP2016540977A5 JP 2016540977 A5 JP2016540977 A5 JP 2016540977A5 JP 2016532124 A JP2016532124 A JP 2016532124A JP 2016532124 A JP2016532124 A JP 2016532124A JP 2016540977 A5 JP2016540977 A5 JP 2016540977A5
- Authority
- JP
- Japan
- Prior art keywords
- mutant
- mammal
- beta
- level
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361906811P | 2013-11-20 | 2013-11-20 | |
| US61/906,811 | 2013-11-20 | ||
| PCT/US2014/066658 WO2015077473A1 (en) | 2013-11-20 | 2014-11-20 | Methods and compositions for treating amyloid deposits |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016540977A JP2016540977A (ja) | 2016-12-28 |
| JP2016540977A5 true JP2016540977A5 (https=) | 2017-12-28 |
| JP6592435B2 JP6592435B2 (ja) | 2019-10-16 |
Family
ID=53180142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532124A Active JP6592435B2 (ja) | 2013-11-20 | 2014-11-20 | アミロイド沈着を処置するための方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20170336395A1 (https=) |
| EP (1) | EP3071240B1 (https=) |
| JP (1) | JP6592435B2 (https=) |
| KR (1) | KR20160079891A (https=) |
| AU (1) | AU2014352944A1 (https=) |
| CA (1) | CA2931220A1 (https=) |
| ES (1) | ES2874704T3 (https=) |
| IL (1) | IL245703B (https=) |
| MX (1) | MX2016006584A (https=) |
| WO (1) | WO2015077473A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018045347A1 (en) * | 2016-09-02 | 2018-03-08 | Spark Therapeutics, Inc. | Methods and vectors for treating cns disorders |
| EP3534892A4 (en) * | 2016-11-04 | 2020-05-27 | The Children's Hospital of Philadelphia | GENE TRANSFER COMPOSITIONS, METHODS AND USE FOR TREATING NEURODEGENERATIVE DISEASES |
| JP7616995B2 (ja) * | 2018-11-28 | 2025-01-17 | プリベイル セラピューティクス，インコーポレーテッド | 神経変性疾患のための遺伝子治療 |
| WO2021026495A1 (en) * | 2019-08-07 | 2021-02-11 | Texas Tech University System | Ad36e40rf1: a therapeutic treatment for alzheimer's disease |
| EP4045653A1 (en) * | 2019-10-16 | 2022-08-24 | Cornell University | Gene therapy for alzheimer's disease |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3002156A (en) * | 1961-09-26 | pumped solid state maser | ||
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US6855314B1 (en) | 2000-03-22 | 2005-02-15 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector for transducing brain cells and lung cells |
| US6468524B1 (en) | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
| CA2457145C (en) * | 2001-08-17 | 2010-12-21 | Washington University | Assay method for alzheimer's disease |
| WO2004108922A2 (en) * | 2003-04-25 | 2004-12-16 | The Trustees Of The University Of Pennsylvania | Use of aav comprising a capsid protein from aav7 or aav8 for the delivery of genes encoding apoprotein a or e genes to the liver |
| WO2007022015A1 (en) * | 2005-08-12 | 2007-02-22 | Georgetown University | Methods to evaluate amyloid beta-lowering agents using wild-type mice |
| ES2373048T3 (es) * | 2006-06-08 | 2012-01-30 | Fu Berlin | Análisis para el diagnóstico de la enfermedad de alzheimer basado en la determinación de la proporción de productos de escisión ab de secretasa. |
| US20080234377A1 (en) * | 2007-03-23 | 2008-09-25 | Martek Biosciences Corporation | Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions |
| EP3066979B1 (en) * | 2010-05-24 | 2017-11-01 | The Washington University | Methods of determining amyloid beta turnover in blood |
| ES2745470T3 (es) * | 2011-03-31 | 2020-03-02 | Univ Iowa Res Found | Partícula de AAV2 que comprende una proteína de la cápside de AAV2 y un vector que comprende un ácido nucleico que codifica una tripeptidilo peptidasa 1 (TPP1) para el tratamiento de lipofuscinosis ceroide infantil tardía (LINCL) en un mamífero no roedor mediante inyección intraventricular o administración icv |
| EP2511296A1 (en) * | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
| AU2012282825B2 (en) * | 2011-07-13 | 2016-05-26 | Merck Sharp & Dohme Corp. | Method for detection of amyloid beta oligomers in a fluid sample and uses thereof |
-
2014
- 2014-11-20 MX MX2016006584A patent/MX2016006584A/es unknown
- 2014-11-20 CA CA2931220A patent/CA2931220A1/en not_active Abandoned
- 2014-11-20 IL IL245703A patent/IL245703B/en unknown
- 2014-11-20 WO PCT/US2014/066658 patent/WO2015077473A1/en not_active Ceased
- 2014-11-20 JP JP2016532124A patent/JP6592435B2/ja active Active
- 2014-11-20 KR KR1020167016073A patent/KR20160079891A/ko not_active Ceased
- 2014-11-20 AU AU2014352944A patent/AU2014352944A1/en not_active Abandoned
- 2014-11-20 EP EP14863892.7A patent/EP3071240B1/en active Active
- 2014-11-20 US US15/038,367 patent/US20170336395A1/en not_active Abandoned
- 2014-11-20 ES ES14863892T patent/ES2874704T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tomono et al. | Highly efficient ultracentrifugation-free chromatographic purification of recombinant AAV serotype 9 | |
| JP4559429B2 (ja) | 空キャプシドを実質的に含まない組換えａａｖビリオン調製物を生成するための方法 | |
| Aslanidi et al. | Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? | |
| CN109121395B (zh) | 腺相关病毒载体递送β-肌聚糖和微RNA-29以及肌营养不良症的治疗 | |
| JP2016540977A5 (https=) | ||
| JP2016503405A5 (https=) | ||
| CA2833908C (en) | Cns targeting aav vectors and methods of use thereof | |
| JP2021512072A5 (https=) | ||
| JP2019513393A5 (https=) | ||
| JP2016525347A5 (https=) | ||
| RU2018116076A (ru) | Модифицированные гены атаксии фридрейха и векторы для генной терапии | |
| JP2018148927A5 (https=) | ||
| IL292999A (en) | Compositions and methods of treating amyotrophic lateral sclerosis (als) | |
| JP2020096587A (ja) | キャプシド | |
| WO2016137949A4 (en) | Regulatable expression using adeno-associated virus (aav) | |
| JP2019511570A5 (https=) | ||
| RU2017125234A (ru) | Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний | |
| JP2018531609A5 (https=) | ||
| JP2020527333A5 (https=) | ||
| JP2019513779A5 (https=) | ||
| JP2017510298A5 (https=) | ||
| JP2018510648A5 (https=) | ||
| RU2016104614A (ru) | Вектор aav и анализ на нейтрализующие антитела против aav (аденоассоциированного вируса) | |
| EP2660325A3 (en) | AAV vectors and corresponding nucleotide sequences and methods | |
| JP2022545121A (ja) | Ａａｖ５の単離修飾ｖｐ１カプシドタンパク質 |